The aberrant expression of several immune checkpoints (e.g., PD-1, PDL-1, and CTLA4) in CD34-positive cells has been reported in 34% of MDS patients after an HMA treatment, which may be a poor prognostic factor. The gene discussed is CD274; the disease is myelodysplastic syndrome.